CASSANDRA THOMPSON: Open Payments
NPI 1144396441 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,277 in 46 payments from 10 companies in 2025. Trend: 2023 $2,598 · 2024 $3,041 · 2025 $1,277
Food & beverage: $1,277
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 8 | $281 |
| Otsuka America Pharmaceutical, Inc. | 8 | $249 |
| Neurocrine BioSciences, Inc. | 3 | $191 |
| Lundbeck LLC | 9 | $186 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $181 |
| Vanda Pharmaceuticals Inc. | 2 | $62 |
| Alkermes, Inc. | 3 | $56 |
| Janssen Pharmaceuticals, Inc | 1 | $33 |
| ABBVIE INC. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
Products named: COBENFY, ABILIFY ASIMTUFII, INGREZZA, CAPLYTA, ABILIFY MAINTENA, REXULTI, ARISTADA, FANAPT.
Industry payments across DC — which companies pay providers there.
